COMPANY PROFILE

Myome

Explore full profile

Helps identify genes that cause disease and act based on leading science

Palo Alto, United StatesFounded 2017Biotech & Life Sciences

Valuation $100–250M Last recorded · 2022

Headcount 100–500 Current team size

Total funding $10–50M Disclosed equity funding

Unlock exact values

About Myome

MyOme is a biotechnology company specializing in clinical-grade whole genome sequencing to provide a comprehensive picture of disease risk. The company serves families and individuals looking to understand their genetic predispositions to both common and rare diseases. Operating in the genomics and personalized medicine market, MyOme combines advanced machine learning and AI technologies to generate integrated disease risk scores that evolve with lifestyle changes. The business model revolves around offering a single, detailed genetic test that delivers actionable insights over a lifetime, thereby enabling earlier health interventions and better disease management. Revenue is generated through the sale of these genetic tests and associated health insights.

MoreLess Source: Dealroom company data

At a glance

Status: Operational
Founded: 2017
Headquarters: Palo Alto, United States
Employees: 91
Open positions: 9
Dealroom signal: 90.3/100
Industry: Health
Sub-industry: BioTechnology
Sector: Biotech & Life Sciences, Biotechnology, Disease, Biotech and Pharma, Hard Tech, DT and LS, science-based
Technology: Recognition Technology
Business model: Manufacturing
Client focus: b2b
Links: Website LinkedIn

Knowledge graph

Founder mafia, market maps, research and news connected to this company by Dealroom

Funding history

3 recorded events

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
SERIES B✓Equity / VC	Jun 2022	$23M	$92M	Founders Fund · Natera · Healthcare Venture Partners · Sequoia	↗
SERIES BEquity / VC	Dec 2021	$0	—	Norwest Venture Partners	—

Showing the latest 2 of 3 recorded eventsBook a demo for the full funding history →

Growth signals

Myome website traffic

Latest recorded traffic for Myome is 16K monthly website visits, up 33.3% over the last three months. Myome's team grew 28.2% over the past year.

Latest monthly visits16K 3-month web change+33.3% 1-year team growth+28.2%

Monthly website visitsJan 2022–Jul 2026

Explore monthly traffic historyTrack growth over time and compare with peersBook a demo

Summary metrics are public; monthly history is available with a demoCompare with peers →

Open positions

Openings linked to this company in Dealroom

8 distinct openings shownExplore hiring signals →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
STSuzhou Huitherapy Biomedical Technology a high-tech enterprise engaged in the industrialization of comprehensively providing nucleic acid drugs	China	Operational	—	$41M	$138M
ATAlamab TherapeuticsClinical Trial Approval in Australia	Princeton, United States	Operational
TTTeitur TrophicsCyclic peptide therapeutics for neurodegenerative diseases	Aarhus, Denmark	Operational
TTTay TherapeuticsBiotech platform enhancing patient-specific medicines through advanced discovery and development expertise	Dundee, United Kingdom	Operational
ACAceragenDeveloper of therapeutic treatments intended for rare and ultra-rare diseases	Durham, United States	Acquired
RPRectify PharmaceuticalsBreakthrough ABC transporter platform enabling rapid discovery of small molecule therapies for liver, biliary, eye, CNS, and cardiometabolic diseases	Cambridge, United States	Operational
TRtranScripSpecialist pharmaceutical consultancy for the entire product lifecycle	Wokingham, United Kingdom	Acquired
PBPlatinum Bioプラチナバイオ、ゲノム編集、共創 \| プラチナバイオ株式会社 \| 日本	Higashi, Japan	Operational